Albert Einstein College of Medicine Launches BIO-VITAL to Accelerate Gerotherapeutics Development
Key Insights
Albert Einstein College of Medicine has launched BIO-VITAL, a new initiative funded by the Ofer Family Foundation (search) to help biotech and pharmaceutical companies advance therapies targeting the biology of aging.
The program offers industry partners access to more than 30 assays and services across three integrated research cores spanning cellular aging, preclinical models, and human longevity multi-omics.
BIO-VITAL is housed within Einstein's Institute for Geroscience, which has pioneered aging research for over 30 years, with the goal of improving healthspan and delaying age-related diseases including cancer (search), diabetes (search), and cardiovascular disease (search).
Albert Einstein College of Medicine has announced the launch of the Batia and Idan Ofer program for Validation of Interventions Targeting Aging and Longevity (BIO-VITAL), a new translational research initiative designed to bridge the gap between academic geroscience and pharmaceutical industry drug development. The program, housed within Einstein's Institute for Geroscience in the Bronx, New York, aims to help biotechnology and pharmaceutical companies advance therapies that target the fundamental biology of aging.
The launch comes at a time of growing investment in therapies designed to delay or prevent chronic disease by addressing aging itself, rather than treating individual age-related conditions in isolation. BIO-VITAL combines Einstein's decades of leadership in aging research with specialized research cores, proprietary models, and translational capabilities that were previously available primarily in academic settings.
"Aging research at Einstein already has led to multiple scientific breakthroughs," said Nir Barzilai, M.D., professor of medicine and of genetics and co-director of Einstein's Institute for Geroscience and BIO-VITAL. "BIO-VITAL was created to help move those discoveries toward therapies that can target aging biology and delay or prevent multiple age-related diseases, including cancer (search), diabetes (search), and cardiovascular disease (search). By working with industry, we can help move promising interventions toward the clinic more efficiently."
Three Integrated Research Cores
BIO-VITAL offers collaborators access to more than 30 assays and services across three integrated research cores, each led by prominent scientists in the field of geroscience.
The Cellular Aging & Technology Core, directed by Ana Maria Cuervo, M.D., Ph.D., evaluates cellular hallmarks of aging including autophagy, proteostasis, senescence, and mitochondrial dysfunction. The Preclinical Aging Models Core, directed by Derek Huffman, Ph.D., employs proprietary animal models to assess physical, metabolic, cognitive, and behavioral characteristics associated with aging and longevity. The Human Longevity Multi-omics Core, led by Dr. Barzilai and Sofiya Milman, M.D., M.S., validates findings using large-scale human genetics and longevity datasets, leveraging Einstein's longstanding leadership in centenarian and aging research.
Together, these capabilities support blinded drug testing, biomarker discovery, mechanistic studies, target validation, indication selection, and translational strategy development for companies pursuing interventions aimed at extending healthspan.
A Legacy of Geroscience Innovation
Einstein has been a pioneer in geroscience for more than 30 years, with research spanning cellular aging, metabolism, longevity genetics, brain aging, and interventions that promote healthy aging. The Institute for Geroscience integrates expertise across disciplines to advance therapies that improve healthspan and address multiple chronic diseases simultaneously by targeting aging itself.
"For decades, Einstein researchers have helped define many of the fundamental hallmarks of aging and develop technologies to study them," said Dr. Cuervo, distinguished professor of developmental and molecular biology and of medicine, and co-director of Einstein's Institute for Geroscience and BIO-VITAL. "We can now make those findings and tools directly available to industry partners seeking to evaluate how potential therapies affect aging on several levels."
Dr. Huffman, professor of molecular pharmacology and of medicine and co-director of BIO-VITAL, emphasized the program's integrated approach: "Einstein's strength is our ability to connect discoveries across scales—from molecules and cells to whole organisms and human populations. That integrated approach allows us to provide partners with translational insights that are often difficult to obtain within a single research environment. BIO-VITAL is specifically designed to help companies accelerate their geroscience programs."
Philanthropic Foundation and Institutional Strength
Established through support from the Ofer Family Foundation (search), BIO-VITAL further strengthens Einstein's position as a leading center for translational aging research and industry collaboration. The philanthropic investment is supporting expansion of Einstein's research infrastructure, recruitment of scientific talent, and growth of applied geroscience research.
Albert Einstein College of Medicine is one of the nation's premier academic centers for basic science research, clinical investigation, and biomedical education. The institution is home to nearly 1,000 M.D., Ph.D., and M.D./Ph.D. students and more than 2,000 full-time faculty members. Einstein receives approximately $200 million in funding from the National Institutes of Health annually and houses six NIH-funded research centers spanning cancer (search), intellectual and developmental disabilities, clinical and translational research, AIDS, and diabetes (search). In partnership with Montefiore Health System, Einstein advances clinical and translational research to accelerate the pace at which new discoveries become treatments that benefit patients.